GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » ROA %

Revelation Biosciences (FRA:56U0) ROA % : -65.90% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Revelation Biosciences's annualized Net Income for the quarter that ended in Dec. 2023 was €-8.08 Mil. Revelation Biosciences's average Total Assets over the quarter that ended in Dec. 2023 was €12.26 Mil. Therefore, Revelation Biosciences's annualized ROA % for the quarter that ended in Dec. 2023 was -65.90%.

The historical rank and industry rank for Revelation Biosciences's ROA % or its related term are showing as below:

FRA:56U0' s ROA % Range Over the Past 10 Years
Min: -359.86   Med: -287.08   Max: -0.91
Current: -0.91

During the past 4 years, Revelation Biosciences's highest ROA % was -0.91%. The lowest was -359.86%. And the median was -287.08%.

FRA:56U0's ROA % is ranked better than
82.51% of 1555 companies
in the Biotechnology industry
Industry Median: -35.15 vs FRA:56U0: -0.91

Revelation Biosciences ROA % Historical Data

The historical data trend for Revelation Biosciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences ROA % Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROA %
- -378.52 -292.03 -1.34

Revelation Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.88 208.08 -33.71 -70.03 -65.90

Competitive Comparison of Revelation Biosciences's ROA %

For the Biotechnology subindustry, Revelation Biosciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revelation Biosciences's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's ROA % distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's ROA % falls into.



Revelation Biosciences ROA % Calculation

Revelation Biosciences's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-0.11/( (5.195+11.199)/ 2 )
=-0.11/8.197
=-1.34 %

Revelation Biosciences's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-8.08/( (13.323+11.199)/ 2 )
=-8.08/12.261
=-65.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Revelation Biosciences  (FRA:56U0) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-8.08/12.261
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-8.08 / 0)*(0 / 12.261)
=Net Margin %*Asset Turnover
=N/A %*0
=-65.90 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Revelation Biosciences ROA % Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Revelation Biosciences (FRA:56U0) Business Description

Traded in Other Exchanges
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines